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Abstract 
The reverse isotopic response is a rarely encountered phenomenon. The spared lesions 
are various and mainly inflammatory in nature, with herpes zoster infection being the 
most common. A novel case of Stevens-Johnson syndrome triggered by carbamazepine 
sparing the skin area previously affected by herpes zoster infection in a 39-year-old 
Indian female with systemic lupus erythematosus is documented. Several features as well 
as possible pathomechanisms that bear discussion have emerged from this case 
documentation. These may be related to the virus immunity, the underlying autoimmune 
disease (systemic lupus erythematosus) and/or drug metabolism. 
 
Introduction 
Infections are common in patients with systemic lupus erythematosus (SLE) 
throughout the course of their disease and remain a source of morbidity and mortality [1, 
2, 4]. 
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Apart from the host genetic predisposition which may determine the general 
susceptibility to both infections (i.e. herpes zoster) and SLE, a defective cell-mediated 
immunity, a hyperactive humoral immunity associated with polyclonal B-cell activation 
and the adverse effects of immunosuppressive treatment have been demonstrated by 
immunological studies [1, 2, 6]. 
Well-documented cases of Stevens-Johnson syndrome (SJS) and toxic epidermal 
necrolysis occurring at the site of resolved herpes zoster (isotopic response) have been 
reported since the first recognition of this dermatological phenomenon by Wolf et al. [3, 
4] in 1985. 
However, a dermatosis sparing another unrelated and already healed skin disease 
(reverse isotopic response) is a rarely encountered phenomenon [5].  
The spared lesions are various, with the majority being inflammatory in nature [5]. 
Case Report 
A 39-year-old Indian woman with SLE diagnosed in 2003 developed right thoracoabdominal herpes 
zoster in December 2007. The vesicular eruption was preceded by a prodrome of dermatomal pain and 
constitutional symptoms lasting for about 4 days. The patient was treated appropriately with acyclovir 
for 7 days and the herpes zoster resolved uneventfully. 
However, a burning sensation persisted in the affected area and carbamazepine (CBZ) was started 
for postherpetic neuralgia 3 weeks following the clearance of the lesions. Eleven days later, the patient 
developed painful erosions of the oral mucosa, conjunctival hyperemia, purpuric macules and patches, 
and flaccid blisters. Further, the skin detachment was patchy. The striking feature of this new eruption 
was the distinct sparing of the area previously affected by the herpes zoster (fig. 1). 
Serum and lesional skin tissue samples were collected at the time of presentation and a complete 
blood count with differential analysis was normal. A comprehensive metabolic panel revealed 
hypercholesterolemia. Acute phase proteins, liver enzymes, urea/electrolytes/creatinine levels, thyroid 
functional tests, rheumatoid factor and urinalysis were within normal limits. An antinuclear antibody 
titer as well as antibodies to ds-DNA, anti-Ro, and anti-La were negative at the time of presentation. 
Histopathological examination of the lesional skin showed features in keeping with SJS (epidermal 
necrosis, marked dermal edema and sparse perivascular lymphocytic infiltrate; fig. 2). Chest X-ray and 
ECG revealed no abnormalities, and the PPD test was negative. Furthermore, abdominal echography 
disclosed an uncomplicated cyst of the left kidney. The patient’s medical history was relevant for 
bronchial asthma with many recurrent infectious episodes in the past. A remote history of pulmonary 
tuberculosis in 2003 was one of note. 
Taking into consideration her Asian ancestry and under the impression of CBZ-induced SJS, we 
attempted to perform genotyping, but the patient declined the test due to the cost involvement. The 
offending drug was withdrawn and oral prednisone was increased from the maintenance dose of 10 
mg/day she was receiving for her SLE during the past 3 years to 1 mg/body weight/day. She continued 
with azathioprine 100 mg/day along with antibiotics and supportive measures. This led to complete 
resolution of the eruption. 
The patient remained clinically stable during the subsequent 4 months although she had a flare-up of 
SLE in May 2008, which was well controlled with immunosuppressive therapy. One year later in August 
2009, her condition deteriorated rapidly. The patient was admitted with respiratory distress, 
pneumonia/pleuritis, and active SLE. She soon died of complications (septicemia, disseminated 
intravascular coagulation). 
Discussion 
Based on the clinical presentation and the pathology report, a diagnosis of CBZ-
induced SJS with a reverse isotopic phenomenon was established in a patient with SLE. In  
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agreement with other authors reports [6], it was found that herpes zoster reactivation 
occurred when SLE was inactive. The presence of varicella-zoster virus DNA in the early 
lesions after herpes zoster eruption has been inconsistently demonstrated by PCR analysis 
[2]. Negative findings in the current case were in line with this statement. Additionally, 
the negative PPD skin test confirmed the low positive rate for PPD results observed in 
patients with SLE as described previously, suggesting a depressed cell-mediated immunity 
or anergy [7]. 
Allodynia is common in the acute phase of herpes zoster infection and predicts a 
higher likelihood of developing postherpetic neuralgia [7]. CBZ is widely used in the 
treatment of postherpetic neuralgia along with NSAID, opioid analgesics, local anesthetics 
and antiviral therapy [8]. Skin reactions induced by CBZ are usually mild, reversible and 
dose related [8, 9]. Severe idiosyncratic drug reactions can also occur [9]. They are more 
likely to occur during the first 8 weeks of the treatment, when the starting dose is high or 
when CBZ is administered with other anticonvulsants [9]. In the case presented herein, 
SJS developed after 11 days of taking CBZ. 
It is well known that because of genetic variations, humans differ in their response to 
treatments. Genetic markers vary in relation to the ethnicity and the offending drug [8, 
10]. HLA-B*1502 as a marker for CBZ-induced SJS is well established in the Han Chinese 
population by different studies [10]. A significant association between CBZ-triggered SJS 
and HLA-B*1502 genotype has also been demonstrated among the Indians, particularly 
in the Hindu community [8, 10, 11]. 
What makes a lesional area protected by the original disease (herpes zoster) and 
resistant to the offensive of a secondary event (drug-induced SJS) remains speculative. 
Several possible pathomechanisms may be related to the virus (VZV) immunity, the 
underlying autoimmune disease (SLE) and/or drug metabolism. It has been hypothesized 
that the virus could alter the skin immune system locally and elicit a predominantly Th1 
cytokine profile with overexpression of TNF-α, IFN-γ, IL-2, and IL-5 [7, 12]. It is possible 
that such cytokines locally inhibit the immunological aberrations responsible for SJS. 
In addition, VZV has a variety of immune evasion mechanisms that limit the 
presentation of viral peptides by MHC class I and II; these may persist and remain hidden 
from the immune system [12]. These viral peptides and/or tissue antigens altered by the 
virus may induce an atypical immune response.  
The concept of epitope spreading, whereby the tissue damage from a primary 
inflammatory process causes the release of previously sequestered antigen, leading to a 
secondary autoimmune response against the newly released antigen, may provide us with 
a possible explanation [13]. In this case, there were some configurational changes within 
the skin antigens, perhaps due to SLE or its treatment, which may have been sequestered, 
and it was only when another triggering event such as herpes zoster occurred that the 
secondary autoimmune response developed. The latter was probably altered by the 
concomitant use of immunosuppressive therapy. 
A genetic or acquired defect in the drug metabolism (CBZ) in predisposed individuals, 
although plausible, does not explain the sparing of the area previously affected by an 
inflammatory condition. 
To conclude, we document a case of severe CBZ hypersensitivity following herpes 
zoster reactivation with a reverse isotopic phenomenon in a patient presenting an 
interaction of two unfavorable prognostic factors: an underlying autoimmune systemic 
disease (SLE) and a possible genetic predisposition.  
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The case presented in this paper provides some insight into the possible etiological 
mechanisms of this rare phenomenon and the complex interplay between antiviral and 
antidrug immune responses. 
 
 
 
 
 
Fig. 1. Widespread purpuric macules and patches triggered by carbamazepine sparing the right 
thoracic (a) and upper abdominal quadrant (b) skin areas previously affected by herpes zoster. 
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Fig. 2. Histopathological examination of the lesional skin showing a thin epidermis with focal vacuolar 
alteration and scattered apoptotic keratinocytes, prominent edema of the papillary dermis, dilated 
capillaries and sparse perivascular lymphocytic infiltrate (HE, original magnification ×10). 
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